Auryon Laser in Treating Symptomatic Infrainguinal Arterial Disease: 1-Year Outcome.

J Invasive Cardiol

Midwest Cardiovascular Research Foundation, 630 East 4th Street, Davenport, IA 52803 USA.

Published: July 2022

AI Article Synopsis

  • The Auryon 355-nm laser atherectomy system demonstrated low target-lesion revascularization (TLR) rates at 6 months and was further examined for its 1-year outcomes in treating infrainguinal arteries.
  • A retrospective study of 56 patients showed no TLR at 6 months, and TLR rates were evaluated at the 1-year mark alongside secondary endpoints like major amputations and mortality.
  • Results revealed that 3.1% of limbs required TLR at 1 year, with the study group predominantly consisting of older males, many exhibiting severe lesions, and a small percentage experiencing mortality within the follow-up period.

Article Abstract

Background: The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the EX-PAD-03 investigational device exemption study and the Auryon single-center experience (SCE) in treating infrainguinal arteries. In this study, we present the 1-year outcomes of the Auryon SCE study on TLR in all comers at a single center.

Methods: The Auryon SCE was a retrospective study that evaluated the outcomes of all comers treated with the Auryon laser for infrainguinal arterial disease. There was no TLR seen at 6-month follow-up. We present the TLR rate at 1 year in the same cohort of patients. TLR rates were obtained from medical record review of patients enrolled in the study who had completed office visit follow-up at 1 year. Secondary endpoints included unplanned major amputation and total mortality. Kaplan-Meier survival analysis was performed to estimate the freedom from TLR rate following index procedure. Statistical differences were analyzed for ankle-brachial index (ABI) between baseline and 1 year.

Results: A total of 56 patients (65 procedures, 70 lesions) were enrolled. The mean age was 70.9 ± 10 years, with 66.1% males, 48.2% diabetics, and 25% demonstrating limb ischemia. Of the 70 lesions, 31.4% had severe calcification, 38.6% were chronic total occlusions, and 48.6% were de novo disease (in-stent restenosis, 29.6%). Stenting was performed in 24/70 lesions (34.3%), with 11/70 (15.7%) bailout procedures. Embolic filters were used in 26/65 procedures (40%). The majority of treated lesions were femoropopliteal (90.0%); of all procedures, 29.2% had 2 or more prior interventions. Drug-coated balloon usage was 47.1% Lutonix (BD/Bard), 27.1% In.Pact (Boston Scientific), and 1.4% both in all lesions treated. Distal embolization occurred in 1/65 procedures (1.5%). At 1 year, mortality occurred in 3/56 patients (5.4%). Of 65 limbs treated, 2 (3.1%) had major amputation at 1 year. The probability of freedom from TLR was 83.7%.

Conclusion: In a realworld cohort of patient with complex disease, the Auryon laser had excellent freedom from TLR at 1 year.

Download full-text PDF

Source
http://dx.doi.org/10.25270/jic/22.00155DOI Listing

Publication Analysis

Top Keywords

auryon laser
12
freedom tlr
12
infrainguinal arterial
8
arterial disease
8
tlr
8
tlr 6-month
8
6-month follow-up
8
auryon sce
8
tlr rate
8
major amputation
8

Similar Publications

A Laser Atherectomy-Thrombectomy System for Primary Management of Acute Limb Ischemia.

J Vasc Interv Radiol

December 2024

Department of Interventional Radiology, Mallinckrodt Institute of Radiology, 510 S Kingshighway Blvd, St. Louis, MO 63110.

Purpose: To evaluate the primary use of a laser atherectomy-thrombectomy system in patients with acute limb ischemia (ALI).

Materials And Methods: A single-center retrospective review of patients presenting with ALI (14 days or less) from August 2021 to February 2024 treated primarily with a laser atherectomy-thrombectomy system (Auryon; Angiodynamics, Queensbury, New York) was performed. Technical success was defined by resolution of the acute occlusion with adequate inflow and outflow with pedal signals detectable by handheld doppler ultrasound.

View Article and Find Full Text PDF

The 355 nm Auryon laser (AngioDynamics, Inc., Latham, New York) has been shown to be effective and safe in treating various morphology lesions in the femoropopliteal arteries. There are limited data on the Auryon laser in treating below-the-knee (BTK) arteries in patients with chronic limb-threatening ischemia.

View Article and Find Full Text PDF

Treatment effect of medial arterial calcification in below-knee after Auryon laser atherectomy using micro-CT and histologic evaluation.

Cardiovasc Revasc Med

December 2023

CVPath Institute, Gaithersburg, MD, USA; University of Maryland, School of Medicine, Baltimore, MD, USA. Electronic address:

Article Synopsis
  • The study investigated the occurrence of medial arterial calcification (MAC) fractures after using the Auryon laser atherectomy on human cadaver limbs with atherosclerosis.
  • Two calcified arterial sections were treated and analyzed using micro-CT and histology to assess calcium disruption.
  • Results indicated that the Auryon laser treatment led to significant fractures in 6 out of 9 zones, particularly in areas with larger arcs of uninterrupted calcification, suggesting it may be an effective therapy for calcified arterial lesions.
View Article and Find Full Text PDF

Trends in outcomes associated with the use of Auryon atherectomy system in a real-world setting.

Cardiovasc Revasc Med

December 2023

Endovascular Consultants of Colorado, Lone Tree, CO 80124, United States of America. Electronic address:

Background: While endovascular approaches are considered first line treatment for stenosis or occlusion of the lower limb arteries, major dissections and embolic events remain procedural risks. Newer technologies are needed which limit these complications while achieving desired clinical outcomes.

Methods: The Auryon atherectomy system (AngioDynamics) consists of a 355-nm wavelength solid-state Nd:YAG short pulse laser combined with dedicated optical catheters.

View Article and Find Full Text PDF

Auryon Laser in Treating Symptomatic Infrainguinal Arterial Disease: 1-Year Outcome.

J Invasive Cardiol

July 2022

Midwest Cardiovascular Research Foundation, 630 East 4th Street, Davenport, IA 52803 USA.

Article Synopsis
  • The Auryon 355-nm laser atherectomy system demonstrated low target-lesion revascularization (TLR) rates at 6 months and was further examined for its 1-year outcomes in treating infrainguinal arteries.
  • A retrospective study of 56 patients showed no TLR at 6 months, and TLR rates were evaluated at the 1-year mark alongside secondary endpoints like major amputations and mortality.
  • Results revealed that 3.1% of limbs required TLR at 1 year, with the study group predominantly consisting of older males, many exhibiting severe lesions, and a small percentage experiencing mortality within the follow-up period.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!